Pasithea Therapeutics Cor... (KTTA)
NASDAQ: KTTA
· Real-Time Price · USD
0.89
0.01 (1.14%)
At close: Jun 06, 2025, 3:59 PM
0.88
-1.51%
After-hours: Jun 06, 2025, 05:46 PM EDT
Company Description
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders.
It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine.
The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Pasithea Therapeutics Corp.
| Country | United States |
| IPO Date | Sep 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Dr. Tiago Reis Marques M.D., Ph.D. |
Contact Details
Address: 1111 Lincoln Road Miami Beach, Florida United States | |
| Website | https://www.pasithea.com |
Stock Details
| Ticker Symbol | KTTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001841330 |
| CUSIP Number | 70261F103 |
| ISIN Number | US70261F2020 |
| Employer ID | 85-1591963 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Tiago Reis Marques M.D., Ph.D. | Chief Executive Officer & Director |
| Daniel H. Schneiderman | Chief Financial Officer |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder, MD & Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 14, 2025 | 4 | Filing |
| May 12, 2025 | SCHEDULE 13G | Filing |
| May 12, 2025 | SCHEDULE 13G | Filing |
| May 09, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 09, 2025 | SCHEDULE 13G | Filing |
| May 07, 2025 | 8-K | Current Report |
| May 07, 2025 | 424B4 | Filing |
| May 01, 2025 | S-1 | Filing |